TS Financial Group (TSFG)’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-50
Closed -$2K – 671
2026
Q2
$2K Hold
50
– – ﹤0.01% 764
2026
Q1
$2K Hold
50
– – ﹤0.01% 731
2025
Q4
$1K Hold
50
– – ﹤0.01% 765
2025
Q3
$1K Hold
50
– – ﹤0.01% 778
2025
Q2
$1K Hold
50
– – ﹤0.01% 752
2025
Q1
$1K Hold
50
– – ﹤0.01% 747
2024
Q4
$1K Hold
50
– – ﹤0.01% 692
2024
Q3
$2K Sell
50
-50
-50% -$1.9K ﹤0.01% 677
2024
Q2
$4K Hold
100
– – ﹤0.01% 589
2024
Q1
$4K Hold
100
– – ﹤0.01% 580
2023
Q4
$4K Hold
100
– – ﹤0.01% 631
2023
Q3
$3K Hold
100
– – ﹤0.01% 741
2023
Q2
$3K Hold
100
– – ﹤0.01% 744
2023
Q1
$4K Hold
100
– – ﹤0.01% 678
2022
Q4
$4K Hold
100
– – ﹤0.01% 683
2022
Q3
$3K Hold
100
– – ﹤0.01% 706
2022
Q2
$3K Hold
100
– – ﹤0.01% 712
2022
Q1
$3K Hold
100
– – ﹤0.01% 697
2021
Q4
$4K Hold
100
– – ﹤0.01% 680
2021
Q3
$5K Hold
100
– – ﹤0.01% 644
2021
Q2
$3K Buy
+100
New +$2.74K ﹤0.01% 694

Other funds holding CLDX

TS Financial Group (TSFG)'s CLDX Position: Q3 2026 in Review

TS Financial Group (TSFG) sold out of Celldex Therapeutics (CLDX) in Q3 2026, closing a stake of 50 shares — an estimated $2K sold.

TS Financial Group (TSFG) first reported a position in CLDX in Q2 2021 and held it in 21 quarters. The position peaked at $5K in Q3 2021. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • TS Financial Group (TSFG) reported no remaining Celldex Therapeutics position as of Q3 2026 after selling out during the quarter.
  • TS Financial Group (TSFG) sold 50 Celldex Therapeutics shares in Q3 2026, an estimated $2K.
  • TS Financial Group (TSFG) first reported a position in Celldex Therapeutics in Q2 2021 and held it in 21 quarters.
  • TS Financial Group (TSFG)'s Celldex Therapeutics position peaked at $5K in Q3 2021.
  • 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on TS Financial Group (TSFG)'s 13F filing for Q3 2026, filed 23 Oct 2026.